Growth Disorder
14
1
1
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
7.1%
1 terminated out of 14 trials
91.7%
+5.2% vs benchmark
29%
4 trials in Phase 3/4
18%
2 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (14)
Evaluation of Children With Endocrine and Metabolic-Related Conditions
Genetic Causes of Growth Disorders
French National Registry of Children Born Small for Gestational Age Treated With Somatropin
Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)
Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation
Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
Effect of Growth Hormone in Children With Growth Hormone Deficiency
Safety and Efficacy of Long-term Somatropin Treatment in Children
A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects
Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers
Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature
Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height
Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature